A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

For sickle cell disease, the FDA has approved a CRISPR/Cas9 therapy that silences the Bcl11a gene to increase fetal hemoglobin production. In osteogenesis imperfecta, studies have demonstrated the ...

CRISPR and Vertex's two phase 1/2 studies in thalassaemia and SCD – called CLIMB-111 and CLIMB-211, respectively – have now recruited 19 patients. They are due to enrol 45 apiece, and are ...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can go ahead, after the FDA lifted a hold on a review. The companies had applied ...

which has a high prevalance of both sickle-cell disease and beta-thalassemia. But for CRISPR to transform medicine it will have to expand beyond ruinously expensive cures for diseases that require ...

I have to admit, I raised an eyebrow when studying Crispr Therapeutics' results. I was expecting to see some details of Casgevy's revenue performance since it was approved to treat Sickle Cell ...